| 产品描述: | NF-κB 抑制剂;NF-κB Inhibitors;产品介绍CBL0137 (Curaxin-137)是一种 histone chaperone FACT (facilitates chromatin transcription) 的抑制剂,可同时抑制 NF-κB 并激活 p53,对应的EC50值分别为0.47 μM和0.37 μM。;InformationCBL0137 CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively.TargetsFACT ; p53 (Cell-free assay); NF-κB (Cell-free assay) ; 0.37 μM(EC50); 0.47 μM(EC50) |
| 体内研究: |
CBL-0137 单独处理组和 CBL-0137 与 Gemcitabine 联合治疗组的样本均显示出大面积坏死灶、大量凋亡小体以及肿瘤细胞丢失。亚最佳剂量 (50 至 60 mg/kg) 的 CBL-0137 与最大耐受剂量 (MTD) (90 mg/kg) 相比,能够增强 Gemcitabine 的抗肿瘤活性,这体现在联合治疗组之间无统计学显著差异。CBL0137 通过消耗参与转录延伸的活性 FACT 池来抑制 FACT 功能。 CBL-0137 以 30 mg/kg/天的无毒剂量进行灌胃给药,采用 5 天用药/2 天停药的给药方案,可抑制结肠癌 (DLD-1)、肾细胞癌 (Caki-1) 和黑色素瘤 (Mel-7) 肿瘤细胞系异种移植瘤以及胰腺导管腺癌患者移植手术标本的肿瘤生长。 |
| 参考文献: |
1. Barone TA, et al. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro Oncol. 2017 Feb 1;19(2):186-196. h 2. Burkhart C, et al. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget. 2014 Nov 30;5(22):11038-53. 3. Ehteda A, et al. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep. 2021 Apr 13;35(2):108994. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.972 ml |
14.862 ml |
29.724 ml |
| 5 mM |
0.594 ml |
2.972 ml |
5.945 ml |
| 10 mM |
0.297 ml |
1.486 ml |
2.972 ml |
| 50 mM |
0.059 ml |
0.297 ml |
0.594 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |